Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Sharyar Samadi

Pediatric Otolaryngology Paramus, NJ Medical Doctor

NPI 1124075460 CMS profile 232937

10 Forest Ave, 100, Paramus, NJ 07652

Open in the dashboard

General payments

$654

20 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Sharyar Samadi of Paramus, NJ is reported in the CMS Open Payments database as having received $654 across 20 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Pediatric Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $60 2
2023 General $36 1
2022 General $180 6
2021 General $25 2
2020 General $54 3
2019 General $299 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sharyar Samadi
  • Pediatric Otolaryngology median
  • Middle half of Pediatric Otolaryngology
  • National median

In program year 2025, general payments to Sharyar Samadi were reported at $0. Among 368 Pediatric Otolaryngology profiles paid that year, the median was $172 and the middle half received between $78 and $412.

Show as a table
Year Sharyar Samadi Pediatric Otolaryngology median Middle half National median
2019 $299 $127 $51–$271 $163
2020 $54 $64 $31–$165 $114
2021 $25 $88 $26–$225 $132
2022 $180 $122 $43–$316 $149
2023 $36 $128 $52–$340 $160
2024 $60 $150 $65–$384 $164
2025 $0 $172 $78–$412 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Stryker Corporation $279 6 payments
  2. Intersect ENT, Inc. $138 3 payments
  3. Aerin Medical Inc. $105 4 payments
  4. Medtronic USA, Inc. $40 2 payments
  5. Inspire Medical Systems, Inc. $36 1 payment
  6. Pacira Pharmaceuticals Incorporated $17 1 payment
  7. Acclarent, Inc $16 1 payment
  8. Cumberland Pharmaceuticals, Inc. $12 1 payment
  9. Eyevance Pharmaceuticals LLC $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $654 20 payments
Products named General payments · program years 2019–2024
  1. GAMMA $130 2 payments
  2. PROPEL $115 2 payments
  3. XPRESS ENT DILATION SYSTEM $94 2 payments
  4. VIVAER STYLUS $44 1 payment
  5. RHINAER STYLUS $44 1 payment
  6. FUSION $40 2 payments
  7. INSPIRE $36 1 payment
  8. ENTELLUS - PATHASSIST SINUS CONFIRMATION TOOLS $28 1 payment
  9. FIAGON NAVIGATION UNIT $26 1 payment
  10. SHAVER SYSTEM $26 1 payment
  11. Other $134 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

1,147

Median for Otolaryngology: 297

Drug cost

$18,866

Median for Otolaryngology: $6,314

Branded share of claims

2.8%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine Hcl Generic 452 $9,351
Fluticasone Propionate Generic 449 $3,863
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 32 $3,774
Levocetirizine Dihydrochloride Generic 99 $984
Ofloxacin Generic 18 $495
Omeprazole Generic 33 $243
Meclizine Hcl Generic 48 $136
Famotidine Generic 16 $20

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$52,104

Medicare's payments for the services billed

Medicare patients

284

Average age 74

Services billed

1,558

151 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 43%
Ischemic heart disease 27%
Chronic kidney disease 20%
Osteoporosis 19%
Depression 17%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Otolaryngology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record